Disclosed herein are uses of a mammalian target of rapamycin (mTOR) inhibitor and chloroquine or analogue thereof in the manufacture of a medicament for treating cancer patients who are not responsive to a hormone therapy and an immunotherapy. In particular, the medicament is used during the hormone therapy and the immunotherapy to sensitize the patients to the hormone therapy and the immunotherapy.
